Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eur J Clin Microbiol Infect Dis ; 40(9): 1821-1832, 2021 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-33783664

RESUMO

Little is known about the role of lineage of strains of Clostridioides difficile (CD) on the clinical presentation of CD infection (CDI) in Latin America, especially regarding the treatment response. We conducted a multicenter, prospective study to investigate the predictive factors and treatment outcomes of CDI in hospitalized patients and to performed phenotypical and molecular characterization of CD strains. A total of 361 diarrheic patients at 5 hospitals from different regions of the country were enrolled. All stool samples were tested for glutamate dehydrogenase (GDH), toxins A and B, and toxin genes using a nucleic acid amplification test (NAAT). Specimens were cultured and susceptibility profile and whole-genome sequencing (WGS) were performed. CDI positivity was 15% (56/377). Predictive factors for CDI were prior use of meropenem (OR 4.09, 95% CI 2.097-7.095; p<0.001), mucus in stools (OR 3.29; 95% CI 1.406-7.722; p=0.006) and neutrophil left-shift with >20% of bands (OR 3.77; 95% IC 1.280-11.120; p=0.016). Overall mortality was 19%, with no deaths attributed to CDI. Oral metronidazole was used in 74% of cases, with 85% of cure and 14% of recurrence. A total of 35 CD isolates were recovered, all of them susceptible to metronidazole and vancomycin. The WGS revealed 17 different STs, six of which were novel. ST42 was the most common ST and hypervirulent strains were not found. Severe CDI were caused by ST42, ST5, ST8, ST48, ST33 and a novel ST667. The ermB gene was more frequently found in isolates of ST42 (p=0.004).


Assuntos
Antibacterianos/uso terapêutico , Clostridioides difficile/genética , Infecções por Clostridium/tratamento farmacológico , Infecções por Clostridium/epidemiologia , Diarreia/microbiologia , Adulto , Idoso , Proteínas de Bactérias/genética , Brasil/epidemiologia , Clostridioides difficile/classificação , DNA Bacteriano/genética , Fezes/microbiologia , Feminino , Hospitalização/estatística & dados numéricos , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Resultado do Tratamento , Sequenciamento Completo do Genoma
2.
Anaerobe ; 66: 102267, 2020 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-33080372
3.
Exp Parasitol ; 218: 107970, 2020 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-32828829

RESUMO

Visceral leishmaniasis (VL) is an anthropozoonosis endemic in Brazil. We included 20 patients with confirmed diagnosis of VL and 20 healthy individuals to evaluate the expression levels of complement receptor 1 (CR1)/CD35 and CR3/CD11b on leukocytes in the peripheral blood and determine their correlation with the clinical state of patients. CR1/CD35 expression increased on CD11b+CD35+granulocytes of patients, while CR1/CD35 and CR3/CD11b expression levels increased on CD14+CD11b+CD35+ monocytes. Among patients, those with severe clinical state had higher expression of CR3/CD11b on CD14+monocytes. The count of CD19+CD35+B lymphocytes reduced in the blood samples from patients. These observed changes may indicate the modulation in CR1/CD35 and CR3/CD11b complement receptor expressionlevels on granulocyte and monocyte populations in response to Leishmania sp.


Assuntos
Antígeno CD11b/metabolismo , Leishmaniose Visceral/imunologia , Leucócitos/metabolismo , Antígeno de Macrófago 1/metabolismo , Receptores de Complemento 3b/metabolismo , Adolescente , Adulto , Idoso , Brasil/epidemiologia , Doenças Endêmicas/estatística & dados numéricos , Feminino , Citometria de Fluxo , Granulócitos/imunologia , Granulócitos/patologia , Humanos , Hipertrofia , Leishmaniose Visceral/sangue , Leishmaniose Visceral/epidemiologia , Leucócitos/imunologia , Fígado/patologia , Contagem de Linfócitos , Masculino , Pessoa de Meia-Idade , Monócitos/imunologia , Monócitos/patologia , Pancitopenia , População Rural , Baço/patologia , População Urbana , Adulto Jovem
4.
Dig Dis Sci ; 62(1): 93-104, 2017 01.
Artigo em Inglês | MEDLINE | ID: mdl-27864656

RESUMO

AIM: The objective was to evaluate the effects of nitric oxide (NO) and hydrogen sulfide (H2S) donors and possible interactions between these two systems in modulating gastric function. METHODS: Mice received saline, sodium nitroprusside (SNP), or sodium hydrosulfite (NaHS), and after 1 h, the animals were killed for immunofluorescence analysis of CSE or eNOS expressions, respectively. Other groups received saline, SNP, NaHS, Lawesson's reagent (H2S donor), PAG + SNP, L-NAME, L-NAME + NaHS, or L-NAME + Lawesson's reagent. Then, the gastric secretions (mucous and acid), gastric blood flow, gastric defense against ethanol, and gastric motility (gastric emptying and gastric contractility) were evaluated. RESULTS: SNP and NaHS increased the expression of CSE or eNOS, respectively. SNP or Lawesson's reagent did not alter gastric acid secretion but increased mucus production, and these effects reverted with PAG and L-NAME treatment, respectively. SNP or NaHS increased gastric blood flow and protected the gastric mucosa against ethanol injury, and these effects reverted with PAG and L-NAME treatments, respectively. SNP delayed gastric emptying when compared with saline, and PAG partially reversed this effect. NaHS accelerate gastric emptying, and L-NAME partially reversed this effect. SNP and NaHS alone induced gastric fundus and pylorus relaxation. However, pretreatment with PAG or L-NAME reversed these relaxant effects only in the pylorus but not in the gastric fundus. CONCLUSION: NO and H2S interact in gastric physiological functions, and this "cross-talk" is important in the control of mucus secretion, gastric blood flow, gastric mucosal defense, and gastric motility, but not in the control of basal gastric acid secretion.


Assuntos
Cistationina gama-Liase/efeitos dos fármacos , Esvaziamento Gástrico/efeitos dos fármacos , Doadores de Óxido Nítrico/farmacologia , Óxido Nítrico Sintase Tipo III/efeitos dos fármacos , Nitroprussiato/farmacologia , Estômago/efeitos dos fármacos , Sulfetos/farmacologia , Alcinos/farmacologia , Animais , Depressores do Sistema Nervoso Central/farmacologia , Cistationina gama-Liase/antagonistas & inibidores , Cistationina gama-Liase/metabolismo , Interações Medicamentosas , Inibidores Enzimáticos/farmacologia , Etanol/farmacologia , Imunofluorescência , Ácido Gástrico/metabolismo , Fundo Gástrico/efeitos dos fármacos , Mucosa Gástrica/efeitos dos fármacos , Mucosa Gástrica/metabolismo , Glutationa/efeitos dos fármacos , Glutationa/metabolismo , Glicina/análogos & derivados , Glicina/farmacologia , Fluxometria por Laser-Doppler , Masculino , Malondialdeído/metabolismo , Camundongos , Muco/efeitos dos fármacos , Muco/metabolismo , Contração Muscular/efeitos dos fármacos , NG-Nitroarginina Metil Éster/farmacologia , Óxido Nítrico Sintase Tipo III/antagonistas & inibidores , Óxido Nítrico Sintase Tipo III/metabolismo , Piloro/efeitos dos fármacos , Ratos , Ratos Wistar , Fluxo Sanguíneo Regional , Estômago/irrigação sanguínea
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...